| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institut National de la Santé et de la Recherche Médicale Unité 659, University of Paris XII, Medical School of Créteil, Henri Mondor Hospital, Department of Dermatology, Créteil, France; and
Sanofi-Aventis, Labège, France
Circulating malignant Sézary lymphocytes result from a clonal proliferation of memory/activated CD4+CD45RO+ T lymphocytes primarily involving the skin. Recently, the CD158k/KIR3DL2 cell surface receptor has been identified to phenotypically characterize these cells. We previously described a mAb termed SC5 that identifies an unknown early activation cell membrane molecule. It is expressed selectively by T lymphocytes isolated from healthy individuals upon activation, and by circulating Sézary syndrome lymphocytes. In addition, we found that SC5 mAb was reactive with all resting T lymphocytes once permeabilized, indicating that SC5 mAb-reactive molecule might present distinct cellular localization according to the T cell activation status. In this study, we show for the first time that SC5 mAb recognizes the intermediate filament protein vimentin when exported to the extracellular side of the plasma membrane of viable Sézary malignant cells. We demonstrate that SC5 mAb is unique as it reacts with both viable malignant lymphocytes and apoptotic T cells. As vimentin is also detected rapidly at the cell membrane surface after normal T lymphocyte activation, it suggests that its extracellular detection on Sézary cells could be a consequence of their constitutive activation status. Finally, as a probable outcome of vimentin cell surface expression, autoantibodies against vimentin were found in the sera of Sézary syndrome patients.
This article has been cited by other articles:
|
|
 |
|
  F. Bossi, L. Rizzi, R. Bulla, A. Debeus, C. Tripodo, P. Picotti, E. Betto, P. Macor, C. Pucillo, R. Wurzner, et al. C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function Blood, April 9, 2009; 113(15): 3640 - 3648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hill, D. A. Bell, W. Brintnell, D. Yue, B. Wehrli, A. M. Jevnikar, D. M. Lee, W. Hueber, W. H. Robinson, and E. Cairns Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice J. Exp. Med., April 14, 2008; 205(4): 967 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Remtoula, A. Bensussan, and A. Marie-Cardine Cutting Edge: Selective Expression of Inhibitory or Activating Killer Cell Ig-Like Receptors in Circulating CD4+ T Lymphocytes J. Immunol., March 1, 2008; 180(5): 2767 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Leong, B. M. Mahesh, J. R. Day, J. D. Smith, A. D. McCormack, G. Ghimire, T. J. Podor, and M. L. Rose Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor J. Leukoc. Biol., February 1, 2008; 83(2): 263 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. van Beijnum, R. P. Dings, E. van der Linden, B. M. M. Zwaans, F. C. S. Ramaekers, K. H. Mayo, and A. W. Griffioen Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature Blood, October 1, 2006; 108(7): 2339 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ortonne, D. Huet, C. Gaudez, A. Marie-Cardine, V. Schiavon, M. Bagot, P. Musette, and A. Bensussan Significance of circulating T-cell clones in Sezary syndrome Blood, May 15, 2006; 107(10): 4030 - 4038. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
